Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31447884 | 0.98 | PARP1 (0.49) | PARP1ALDH1A1KDM4EAURKAGFER | |
| SCHEMBL24101668 | 0.83 | HTR2A (0.56) | PARP1KDM4EAURKAPDK2CCNB2 | |
| SCHEMBL30339480 | 0.83 | HTR2A (0.56) | PARP1KDM4EAURKAPDK2CCNB2 | |
| SCHEMBL24101593 | 0.79 | KDM4E (0.47) | PARP1KDM4EAURKAMAPTPDK2 | |
| SCHEMBL30063679 | 0.79 | KDM4E (0.47) | PARP1KDM4EAURKAMAPTPDK2 | |
| SCHEMBL12950764 | 0.79 | KDM4E (0.50) | PARP1KDM4EAURKAMAPTPDK2 | |
| SCHEMBL46213 | 0.78 | NISCH (0.57) | PARP1KDM4EAURKAALOX15HSD17B10 | |
| SCHEMBL961368 | 0.78 | TAAR1 (0.55) | PARP1KDM4EAURKAPDK2CCNB2 | |
| SCHEMBL2247129 | 0.78 | AURKA (0.40) | PARP1ALDH1A1AURKAMAPTPDK2 | |
| Hydrochloric Acid SCHEMBL14892523 | 0.77 | NISCH (0.55) | PARP1KDM4EAURKAALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3817748-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-6858622-B2 | Cycloalkano-indole and -azaindole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20020147209-A1 | Cycloalkano-indole and -azaindole derivatives | MUELLER ULRICH (DE) | 2002-10-10 | — | — | US | disclosed |
| US-20020055635-A1 | Cycloalkano-indole and -azaindole derivatives | MULLER ULRICH (DE) | 2002-05-09 | — | — | US | disclosed |
| US-6291473-B1 | TREATING ANXIETY, DEPRESSION, POST-TRAUMATIC STRESS DISORDER, INFLAMMATORY DISEASES, OBESITY, IN MAMMALS | NEUROGEN CORPORATION | 2001-09-18 | — | — | US | disclosed |
| US-6265431-B1 | ANTICHOLESTEROL DRUGS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-24 | — | — | US | disclosed |
| US-6245775-B1 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-1068205-A1 | AMINOALKYL SUBSTITUTED 5,6,7,8-TETRAHYDRO-9H PYRIMIDINO 2,3-B]INDOLE AND 5,6,7,8-TETRAHYDRO-9H-PYRIMIDINO 4,5-B]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068205-A1 | AMINOALKYL SUBSTITUTED 5,6,7,8-TETRAHYDRO-9H PYRIMIDINO 2,3-B]INDOLE AND 5,6,7,8-TETRAHYDRO-9H-PYRIMIDINO 4,5-B]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051597-A1 | AMINOALKYL SUBSTITUTED 5,6,7,8-TETRAHYDRO-9H PYRIMIDINO[2,3-B]INDOLE AND 5,6,7,8-TETRAHYDRO-9H-PYRIMIDINO[4,5-B]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5684014-A | FOR TREATING ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0705831-A2 | Cycloalkano-indole- and -azaindole derivatives | BAYER AG (DE) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | CRBN, CRKL, CUL4A | PARP1 2805/4885ALDH1A1 4128/4885KDM4E 2339/4885 |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | CRBN, CRKL, CUL4A | PARP1 2805/4885ALDH1A1 4128/4885KDM4E 2339/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PARP1 85/4885ALDH1A1 2776/4885KDM4E 190/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | PARP1 2805/4885ALDH1A1 4128/4885KDM4E 2339/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PARP1 101/4885ALDH1A1 2230/4885KDM4E 223/4885 |
| US-20020147209-A1 | Cycloalkano-indole and -azaindole derivatives | AADAC, IDO1, AADAT | PARP1 663/4885ALDH1A1 1034/4885KDM4E 2676/4885 |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | PARP1 2805/4885ALDH1A1 4128/4885KDM4E 2339/4885 |
| US-20020055635-A1 | Cycloalkano-indole and -azaindole derivatives | ADRB3, AADAT, INMT | PARP1 1900/4885ALDH1A1 1445/4885KDM4E 3593/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | PARP1 101/4885ALDH1A1 2230/4885KDM4E 223/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PARP1 85/4885ALDH1A1 2776/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.